< Back to search
Filter
1

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

for
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative,
Location: Phoenix AZ, Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18 - 54

Code: NCT06918431

Phase2, Recruiting

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

for
Lymphoma, Marginal Zone Lymphoma, MZL
Location: Boston MA
Sponsor: Gottfried von Keudell, MD PhD

Sex: All

Age: 18+

Code: NCT06510309

Phase2, Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

for
Follicular Lymphoma (FL)
Location: Saint John, Boston MA, Quebec, Stony Brook NY,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06091254

Phase3, Recruiting

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

for
Recurrent Diffuse Large B-Cell Lymphoma,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT07042438

Phase2, Recruiting

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

for
Non Hodgkin Lymphoma, Solid Tumor
Location: La Jolla CA
Sponsor: University of California, San Diego

Sex: All

Age: 18+

Code: NCT07222631

Phase1, Phase2, Recruiting

Interested in new lymphoma trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

for
Lymphoma, Lymphoma, Large B-Cell, Diffuse
Location: Boston MA, Miami FL
Sponsor: Jennifer Crombie, MD

Sex: All

Age: 18+

Code: NCT05800366

Phase2, Recruiting

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

for
Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
Location: New York NY
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT07220616

Phase1, Phase2, Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

for
B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia,
Location: Little Rock AR, Springdale AR
Sponsor: Arkansas Children's Hospital Research Institute

Sex: All

Age: 1 - 23

Code: NCT07422337

Recruiting

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

for
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1,
Location: Seattle WA
Sponsor: University of Washington

Sex: All

Age: 18+

Code: NCT07224100

Phase2, Recruiting

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

for
Primary Vitreoretinal Lymphoma
Location: Miami FL
Sponsor: Aldeyra Therapeutics, Inc.

Sex: All

Age: 21+

Code: NCT07402876

Phase3, Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

for
Chronic Lymphocytic Leukemia (CLL),
Location: Norfolk VA, Silver Spring MD, Fairfax VA, Durham NC,
Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07221500

Phase2, Recruiting

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

for
Burkitt Lymphoma, Double-Expressor Lymphoma,
Location: Pittsburgh PA, Kansas City KS, Westwood KS, Fairway KS,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07069699

Phase1, Phase2, Recruiting

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

for
Relapsed/Refractory Primary Central Nervous System Lymphoma
Location: Boston MA, Providence RI, New Haven CT, New York NY,
Sponsor: Ono Pharmaceutical Co., Ltd.

Sex: All

Age: 18+

Code: NCT07104032

Phase3, Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

for
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Location: York PA, Bethesda MD, Charlotte NC, Columbus OH,
Sponsor: Tempus AI

Sex: All

Age: 0+

Code: NCT07154823

Recruiting

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

for
Lymphoma, Multiple Myeloma
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18 - 70+

Code: NCT07226934

Recruiting

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

for
CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia,
Location: Cincinnati OH
Sponsor: Zulfa Omer

Sex: All

Age: 18+

Code: NCT07108998

Phase2, Recruiting

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

for
B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: All

Age: 18+

Code: NCT07097363

Phase2, Recruiting

Mosunetuzumab for CLL MRD Clearance

for
Leukemia, Chronic Lymphocytic Leukemia,
Location: Boston MA
Sponsor: Inhye Ahn

Sex: All

Age: 18+

Code: NCT07052695

Phase1, Phase2, Recruiting

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma,
Location: Cincinnati OH
Sponsor: Zulfa Omer

Sex: All

Age: 18+

Code: NCT07014917

Phase2, Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

for
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Location: Baltimore MD, Charlottesville VA, Pittsburgh PA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07003295

Phase2, Recruiting